Issue 78 | January 2019
In the next issue of Pharma Technology Focus, we find out about a new class of cancer therapeutics developed by Cybrexa, which looks to identify combinations of chemotherapy and DNA inhibitors to increase efficacy and reduce toxicity in cancer treatment, and explore the environmental impact of clinical antidepressants entering waters around the UK.
Also, we speak to LNC Therapeutics to find out if the company’s exclusive license agreement with Cornell University for its Christensenella patent family could form the foundation for the first drugs using microbiome bacteria, and take a look at a new app developed by Roche, which may help physicians to match patients to clinical trials.
Plus, we examine the results of Eli Lilly’s GIP and GLP-1 receptor agonist, which showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes, and investigate how pharma companies and the supply chain tackle the challenges of controlling an epidemic in an uncontrollable environment.
Editor | Eloise McLennan
Group Editor | Susanne Hauner
Commissioning Editor | Daniel Garrun
Writers | Allie Nawrat, Charlotte Edwards, Sally Turner, Elliot Gardner, Chris Lo
Magazine Designer | Marzia Del Gaone
Graphic Designers | Paulius Zutautas, Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond
Digital Publishing Director | Duncan West
Sales Manager | Nimai Amin
+44 (0) 207 936 6453
Media Partnership Enquiries | Susanne Hauner
Pharma Technology focus is powered by h5mag
read past issues of pharma technology focus HERE
Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.